Pfizer (PFE) Tops Q1 EPS by 7c, Reaffirms FY20 EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. ACN
3. NVDA
4. MU
5. APGE
6. DFTX
7. GOOGL
8. KR
9. MSTR
10. HOOD

Go back to Pfizer (PFE) Tops Q1 EPS by 7c, Reaffirms FY20 EPS Guidance

Pfizer (PFE), Valneva Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15

April 30, 2020 5:59 AM EDT

Pfizer Inc. (NYSE: PFE) and Valneva SE today announced a collaboration to develop and commercialize Valnevas Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical studies.

VLA15 is the only active Lyme disease vaccine program in clinical development today, and covers six serotypes that are prevalent in North America and Europe. The investigational multivalent protein subunit vaccine, VLA15, targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the... More

Pfizer (PFE), BioTech (BNTX) Report Complete Patient Dosing in First Cohort of Ph. 1/2 Trial of COVID-19 vaccine candidates in Germany

April 29, 2020 5:48 AM EDT

BioNTech SE (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTechs Phase 1/2 clinical trial has been dosed. Twelve study participants were dosed with vaccine candidate BNT162 in Germany since dosing began on April 23, 2020. The trial is the first clinical trial of a... More